A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Clinical Trials, Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives

NCT Number: NCT05849298
Phase:
Trial Summary: The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in pa – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Novartis Pharmaceuticals
Acronym: PSMACare

Pin It on Pinterest